BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI, ", , the Company", , ))))), a leading developer of cellular therapies for neurodegenerative diseases, today announced that it received a notification letter (the "Notification Letter on Compliance") on April 10, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq"), indicating that the Company has regained compliance with the minimum market value of listed securities requirement set forth under Nasdaq Listing Rule 5550(b)(2) (the "Rule").
BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule
Company Profile
Thu. 11 Apr 2024, 6:02am ET
Benzinga
Government, News, Regulations, SEC